Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (NASDAQ:ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee (the "Transaction Committee"), said, "The AC

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GL

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmac

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 – SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEW

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0ESK-001 was generally well-tolerated at one year, with no new safety findingsData further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasisPhase 3 ONWARD program ongoing with topline data expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) -- Alumis I

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN) and Alumis Inc. (NASDAQ:ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immu

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis") and ACELYRIN, INC. (NASDAQ:SLRN) ("ACELYRIN") today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases. The combined company will have a significantly strengthened financial posi

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (NASD

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4/A - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00

Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight

Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00

Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00

Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00

Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

EFFECT - ALUMIS INC. (0001847367) (Filer)

424B3 - ALUMIS INC. (0001847367) (Filer)

10-K/A - ALUMIS INC. (0001847367) (Filer)

S-4 - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

EFFECT - ALUMIS INC. (0001847367) (Filer)

424B3 - ALUMIS INC. (0001847367) (Filer)

S-4/A - ALUMIS INC. (0001847367) (Filer)

S-4 - ALUMIS INC. (0001847367) (Filer)

8-K - ALUMIS INC. (0001847367) (Filer)

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13G - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)